Description
TAS-116 is an investigational medication currently being studied in clinical trials. It is being evaluated as a potential treatment for various types of cancer, including colorectal cancer. The trials are in early phases (Phase 1), meaning they primarily focus on determining the safest dose and understanding how the drug is processed by the body. TAS-116 is being tested alone and in combination with other cancer treatments, such as chemotherapy agents (like 5-Fluorouracil, Gemcitabine, Nab-Paclitaxel) and targeted therapies (like Bevacizumab, Ramucirumab). Some trials are specifically looking at patients whose tumors have certain genetic changes (mutations) like EGFR, KRAS, MET, NRAS, VEGF, or specific levels of PD-L1 expression. The goal of these early trials is to assess the safety and potential effectiveness of TAS-116 in these patient groups. It is not yet approved for use in colorectal cancer.
Mechanism of Action
TAS-116 is being investigated as a potential cancer treatment. The specific way it works (its mechanism of action) is still being studied in clinical trials. It is designed to target processes involved in cancer cell growth and survival. Further research is needed to fully understand its molecular target and how it interacts with cancer cells.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Category | Other Medications |
 EMA Status | Experimental |
 Spain Access | Not available |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.